Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM)

| January 12, 2017

article image
Big-name mergers and acquisitions, takeovers, asset acquisition, partnerships, and more are all standard fare for the event, and this means the industry watches it incredibly closely as it plays out. There are, of course, also plenty of presentations, many of which reveal data that – as yet – hasn’t hit markets. As a result, this compounds the deal driven volatility, and can make things pretty tough to track. With this in mind, and in an attempt to add some clarity to the madness, here are two of the biggest movers so far, and what’s driving the action in both.

Spotlight

Dow AgroSciences

Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, began in 1989 as DowElanco, a joint venture between the plant sciences businesses of The Dow Chemical Company and Eli Lilly and Company. In 1997, DowElanco was renamed Dow AgroSciences when Dow acquired 100 percent ownership of the business from Lilly.

OTHER ARTICLES

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Learning How FoxA2 Helps Turn Stem Cells into Organs

Article | March 18, 2020

Scientists at the Perelman School of Medicine at the University of Pennsylvania discovered early on in each cell, FoxA2 simultaneously binds to both the chromosomal proteins and the DNA, opening the flood gates for gene activation. The discovery, “Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones,” published in Nature Genetics, helps untangle mysteries of how embryonic stem cells develop into organs, according to the researchers. “Gene network transitions in embryos and other fate-changing contexts involve combinations of transcription factors. A subset of fate-changing transcription factors act as pioneers; they scan and target nucleosomal DNA and initiate cooperative events that can open the local chromatin. However, a gap has remained in understanding how molecular interactions with the nucleosome contribute to the chromatin-opening phenomenon,” write the investigators.

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

Dow AgroSciences

Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, began in 1989 as DowElanco, a joint venture between the plant sciences businesses of The Dow Chemical Company and Eli Lilly and Company. In 1997, DowElanco was renamed Dow AgroSciences when Dow acquired 100 percent ownership of the business from Lilly.

Events